[Adrenergic therapy and vigilance: beta-2 sympathomimetic aerosols in asthma]. 1988

M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
Centre Régional de Pharmacovigilance, Caen.

It has been established that the use of beta-2 sympathomimetic aerosols is a safe and efficacious treatment of asthma. Unexpected cases of sudden death amongst insufficiently-treated patients or patients who stopped their treatment are not linked with the use of these drugs. To assess the risk of possible "receptor desensitization" it is necessary to notify these accidents to the Committee on Safety of Drugs and to take into consideration the opposite results of further administration and termination of treatment.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
January 1985, Clinical pharmacy,
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
May 1969, Der Internist,
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
April 1973, The Indian journal of chest diseases,
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
August 1992, Pneumologie (Stuttgart, Germany),
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
March 1969, New York state journal of medicine,
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
January 1993, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
September 1970, The Journal of allergy,
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
April 1973, Chest,
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
January 1984, Clinical pharmacy,
M Moulin, and F C Hugues, and M C Bigot, and B Mosquet
March 2001, Current opinion in pulmonary medicine,
Copied contents to your clipboard!